Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

BACKGROUND: Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of these benefits also in lower kidney-risk T2D populations n...

Descripción completa

Detalles Bibliográficos
Autores principales: Schechter, Meir, Melzer-Cohen, Cheli, Rozenberg, Aliza, Yanuv, Ilan, Chodick, Gabriel, Karasik, Avraham, Kosiborod, Mikhail, Mosenzon, Ofri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375057/
https://www.ncbi.nlm.nih.gov/pubmed/34407822
http://dx.doi.org/10.1186/s12933-021-01362-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375057/
https://www.ncbi.nlm.nih.gov/pubmed/34407822
http://dx.doi.org/10.1186/s12933-021-01362-y

Ejemplares similares